TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22970149
Drug: 600 mg/day
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/day DHA (from algal oil)
Study: 31154289
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group (Etanercept + Methotrexate)
Study: 18991147
Drug: Low-dose doxycycline
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose doxycycline in a hydrogel
Study: 23355361
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of ranolazine 1,500 mg
Study: 11911409
Drug: Cytosine arabinoside
Normalized name: Cytosine arabinoside
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytosine arabinoside (ara-C) dose escalation to 15 and 20 mg/m2/d for 1-10 days
Study: 9840848
Drug: Ropivacaine at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine at 8 mL/hour
Study: 2124243
Drug: Interferon gamma
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon gamma (100 micrograms per subcutaneous injection, daily for the first 2 weeks, then 3 times per week)
Study: 2124243
Drug: Interferon gamma
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon gamma (100 micrograms per subcutaneous injection)
Study: 12087008
Drug: Orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120 mg t.i.d.
Study: 23524622
Drug: Papaya preparation
Normalized name: Carica papaya preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papaya preparation (Caricol®)
Study: 9803047
Drug: Controlled-release (CR)
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release (CR) oxycodone 30 mg every 12 hr
Study: 20032170
Drug: Home blood
Normalized name: LifeSource Aneroid Home Blood Pressure Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home blood pressure monitoring (at least weekly measurements)
Study: 21149498
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) monotherapy, 20 mg/weekly
Study: 31620931
Drug: Pertuzumab plus
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pertuzumab plus trastuzumab and chemotherapy
Study: 1563884
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (10 capsules, 3 g per day, containing 1.8 g eicosapentaenoic acid and 1.2 g docosahexaenoic acid)
Study: 22612765
Drug: Individually tailored
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually tailored oral health educational programme (ITOHEP) based on cognitive behavioural strategies
Study: 11305263
Drug: High-phosphorus diet
Normalized name: Phosphorus
DrugBank: Phosphorus (DB14151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-phosphorus diet (3008 mg P and 1995 mg Ca/day for 6 weeks)
Study: 9072602
Drug: 280 mg
Normalized name: levodopa 280 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 280 mg estramustine phosphate 2 times daily
Study: 9776856
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with beta-hydroxybutyrate on uninjured normal cells
Study: 16309958
Drug: Ramelteon 4
Normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramelteon 4 mg
Study: 18565860
Drug: Dronedarone 400
Normalized name: dronedarone 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronedarone 400 mg twice a day
Study: 3055874
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg mifentidine
Study: 24717710
Drug: Traditional injection
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional injection without the aid of the DentalVibe
Study: 1562332
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups administered 4 ml of 4% lidocaine translaryngeally
Study: 7734367
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg cladribine/m2/d
Study: 30219436
Drug: Ginkgo Leaf
Normalized name: Ginkgo leaf
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo Leaf Tablets and Liuwei Dihuang Pills
Study: 26059745
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of extracts from grape seed and skin, green tea, resveratrol, quercetin, ginkgo biloba and bilberry
Study: 26206652
Drug: Goal-Directed Therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-Directed Therapy (GDT) using stroke volume variation
Study: 11878524
Drug: Ropivacaine 2.5
Normalized name: fentanyl-ropivacaine 2.5 mcg/mL-0.1%-0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 2.5 mg with fentanyl 0.025 mg
Study: 11878524
Drug: Bupivacaine 2.5
Normalized name: Sure-Amp BUPivacaine 2.5 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 2.5 mg with fentanyl 0.025 mg
Study: 30630792
Drug: Pure topical
Normalized name: Clarifoam Pure Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pure topical therapy of hydroquinone ointment
Study: 2959439
Drug: Guar granules
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar granules (5 g) sprinkled over food for 4 weeks
Study: 22334123
Drug: Intravenous nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous nicotine (0.5 and 1.0 mg/70 kg)
Study: 7859936
Drug: Low-dose bedtime
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose bedtime insulin/daytime sulfonylurea (BI-DSU)
Study: 18539340
Drug: RUL ECT
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RUL ECT at a fixed dose of 403 mC
Study: 17950161
Drug: Drug and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug and Alcohol Testing (DAT)
Study: 15574078
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of beta-hydroxy beta-methylbutyrate (HMB) per day
Study: 2828412
Drug: 1,25-dihydroxyvitamin D
Normalized name: 1,25-dihydroxyvitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,25-dihydroxyvitamin D (1 microgram daily) in a hypoparathyroid patient
Study: 31541942
Drug: Chlorogenic acid
Normalized name: chlorogenic acid
DrugBank: Chlorogenic Acid (DB12029)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorogenic acid for injection (CAFI) administered intramuscularly
Study: 26957044
Drug: Indoor residual
Normalized name: Cleartime Indoor & Outdoor Allergies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoor residual spraying and long-lasting insecticidal nets (not specified dosage or duration)
Study: 20829069
Drug: Levosimendan at
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan at 0.05 μg/kg/min
Study: 15487806
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (ASC) 0.48 g, 3 times daily for 6 days
Study: 15487806
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ASA and ASC
Study: 15957569
Drug: MEMS feedback
Normalized name: MEM 1003
DrugBank: MEM 1003 (DB05547)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEMS feedback group (bupropion‐SR 150 mg)
Study: 15962644
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine 300 microg (n = 25)
Study: 8110249
Drug: 16-hour transdermal
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 16-hour transdermal nicotine patch
Study: 894647
Drug: Monistat cream
Normalized name: Monistat
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Monistat cream (miconazole nitrate 2%) for 7 days
Study: 10495460
Drug: Immediate zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate zidovudine treatment
Study: 7997375
Drug: D2 receptor
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D2 receptor scintigraphy (123I-IBZM)
Study: 23907785
Drug: Acoustic Coordinated
Normalized name: aconite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acoustic Coordinated Reset (CR) neuromodulation therapy
Study: 1618212
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (50 mg patch, 10 mg.24 h-1)
Study: 26482244
Drug: Onion skin
Normalized name: ONION
DrugBank: Onion (DB10548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onion skin extract powder (approximately 163 mg quercetin)
Study: 10886122
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of lefradafiban
Study: 10886122
Drug: Jejunal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Jejunal administration of lefradafiban
Study: 10886122
Drug: Ileal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ileal administration of lefradafiban
Study: 31139877
Drug: CYP inducers
Normalized name: CYP-001
DrugBank: CYP-001 (DB15739)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP inducers (concurrent medication)
Study: 28699499
Drug: Argan oil
Normalized name: ARGAN OIL
DrugBank: Argan oil (DB14310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argan oil (30 ml per day for 8 weeks)
Study: 17053334
Drug: Psychodynamic inpatient
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychodynamic inpatient treatment (n = 137)
Study: 30572160
Drug: Electroconvulsive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroconvulsive therapy (ECT) thrice weekly for 3–5 weeks
Study: 10516931
Drug: Levofloxacin twice-a-day
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin twice-a-day therapy (200 mg/day for 7 days)
Study: 10516931
Drug: Levofloxacin once-a-day
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin once-a-day therapy (200 mg/day for 7 days)
Study: 2865177
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of antichlamydial antibodies
Study: 23537967
Drug: Ticagrelor 90
Normalized name: ticagrelor 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 90 mg twice daily for 30 days (for all patients)
Study: 19931204
Drug: 24 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 weeks PEG-IFN alpha and ribavirin treatment
Study: 1974399
Drug: Loratadine 20
Normalized name: Loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loratadine 20 mg
Study: 19320851
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 375 μg
Study: 22064208
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) at doses of 0.44, 1.3, or 2.7 g/d
Study: 14602781
Drug: 300 microg
Normalized name: Voglibose 300 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 microg E2 combined with oral dydrogesterone (20 mg/d) during the last 14 days
Study: 11803348
Drug: rabbit antithymocyte
Normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabbit antithymocyte globulin (ATG) 1.25 mg/kg on alternate days, starting at a median interval of 11 days after BMT
Study: 14710104
Drug: Prenatal vitamin
Normalized name: Prenatal Vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal vitamin with 400 IU of vitamin E and 500 mg of vitamin C
Study: 15899030
Drug: Infliximab therapy
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab therapy (discontinued after 3 years)
Study: 9653638
Drug: Coping-oriented group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coping-oriented group therapy
Study: 12588464
Drug: Sumatriptan (SUM)
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sumatriptan (SUM) 6 mg s.c. injected in the morning and afternoon
Study: 12589283
Drug: Weekly Gel
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly Gel (Karigel‐N for 4 minutes weekly)
Study: 18791483
Drug: Herbal combination
Normalized name: HERBAL MISCELLANEOUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal combination therapy (Hypericum perforatum and Vitex agnus-castus)
Study: 14581124
Drug: Oral delta-9-THC
Normalized name: delta-9-THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral delta-9-THC 5 mg
Study: 31025878
Drug: Insulin patch
Normalized name: CeQur Simplicity 4-Day Insulin Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin patch
Study: 25099185
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate (1000 mg, once daily) and prednisolone (5 mg, twice daily)
Study: 19442491
Drug: Tapering off
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapering off current antipsychotic over 4 weeks with aripiprazole (10 mg)
Study: 19442491
Drug: Tapering off
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapering off current antipsychotic over 6 weeks with aripiprazole (10 mg)
Study: 22838970
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme (ACE) inhibitors
Study: 7923485
Drug: Incontinent patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incontinent patients with rectal prolapse
Study: 10702450
Drug: Epidural droperidol
Normalized name: Droperidol
DrugBank: Droperidol (DB00450)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural droperidol 1.25 mg
Study: 10702450
Drug: Epidural droperidol
Normalized name: Droperidol
DrugBank: Droperidol (DB00450)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural droperidol 2.5 mg
Study: 10702450
Drug: Epidural droperidol
Normalized name: Droperidol
DrugBank: Droperidol (DB00450)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural droperidol 5.0 mg
Study: 28644348
Drug: Lactulose mannitol
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lactulose mannitol ratio (L:M) test
Study: 28381246
Drug: FIT programme
Normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: FIT programme (daily group handwashing with soap, toothbrushing with fluoride toothpaste, biannual school-based deworming, construction of handwashing facilities)
Study: 7793298
Drug: Insulin sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin sensitivity in obese FH subgroup
Study: 19890274
Drug: Epoetin-alfa treatment
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin-alfa treatment with high hemoglobin target (13.5 g/l)
Study: 10629708
Drug: Organ sparing
Normalized name: argan oil
DrugBank: Argan oil (DB14310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Organ sparing treatment (sectorial resection +/‐ axillary dissection)
Study: 7861019
Drug: Prior zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prior zidovudine therapy
Study: 956103
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg ascorbic acid
Study: 25277061
Drug: Flurbiprofen lozenges
Normalized name: flurbiprofen Oral Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen lozenges (new generic formulation by Epifarma Srl)
Study: 20023215
Drug: Concurrent rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Concurrent rituximab (375 mg/m2) plus infusional EPOCH chemotherapy
Study: 10629434
Drug: d-fenfluramine (D-FEN)
Normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-fenfluramine (D-FEN) 15 mg
Study: 10629434
Drug: ipsapirone (IPS)
Normalized name: IP-2018
DrugBank: IP-2018 (DB19049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ipsapirone (IPS) 10 mg
Study: 2735338
Drug: Sucralfate suspension
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucralfate suspension
Study: 8997012
Drug: Antacid suspension
Normalized name: Antacid Suspension
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antacid suspension
Study: 28734822
Drug: Icotinib 125
Normalized name: niacin
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icotinib 125 mg orally (three times per day)
Study: 29855972
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (IGlar)
Study: 25803346
Drug: Balloon-expandable stent
Normalized name: castor fiber scent gland secretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balloon-expandable stent plus medical therapy (stent group; n=59)
Study: 21734600
Drug: Saccharomyces boulardii
Normalized name: Saccharomyces boulardii
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharomyces boulardii (200 mg, twice per day for 5 days)
Study: 22871888
Drug: β-blocker
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β-blocker
Study: 11880017
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg
Study: 9543445
Drug: gp160 in
Normalized name: Gp160 Vaccine
DrugBank: VaxSyn (DB17827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gp160 in alum over a 2‐year period in combination with placebo (n = 32)
Study: 26202922
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC)
Study: 7898078
Drug: Simvastatin 5
Normalized name: simvastatin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 5 mg
Study: 20031551
Drug: Pravastatin 10
Normalized name: pravastatin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 10 mg
Study: 10586394
Drug: Aztreonam 1000
Normalized name: aztreonam 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aztreonam 1000 mg
Study: 24425846
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) gel
Study: 24673738
Drug: Lactobacillus casei
Normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus casei 01 supplementation (10^8 CFU, one capsule daily for 8 weeks)
Study: 24993395
Drug: Cranberry capsules
DrugBank: Cranberry (DB10631)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry capsules (72 mg proanthocyanidins)
Study: 27512927
Drug: Rifaximin 1200
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin 1200 mg daily for 6 months
Study: 25393287
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg zinc sulphate daily for three months
Study: 9585822
Drug: Azelastine nasal
Normalized name: azelastine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine nasal spray
Study: 19786940
Drug: Full-dose r-PA
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose r-PA
Study: 15497256
Drug: Concurrent memory
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent memory task present
Study: 24691436
Drug: Warfarin (dose-adjusted)
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin (dose-adjusted)
Study: 1717776
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of benazepril (10 mg) and cadralazine (5 mg)
Study: 3190990
Drug: Bupivacaine HCl
Normalized name: bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine HCl 1.4 mg kg‐1 by i.m. injection after two oral doses of 400 mg cimetidine
Study: 29211967
Drug: AMPH EROS
Normalized name: AMPH-b
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AMPH EROS (10-20 mg/day)
Study: 19734131
Drug: Exercises and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercises and usual treatment (Control)
Study: 2194055
Drug: Rokitamycin (RKM)
Normalized name: rokitamycin
DrugBank: Rokitamycin (DB13409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rokitamycin (RKM) dry syrup at approximately 30 mg/kg body weight for 5 days
Study: 17914134
Drug: Calcium lactate
Normalized name: Calcium Lactate
DrugBank: Calcium lactate (DB13231)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium lactate (daily dose about 800 mg calcium)